attachment 1 list of Drug Products.xlsx

This is a drug products forecast list prepared for the FDA's Center for Drug Evaluation and Research (CDER) under solicitation CDER-2026-132721 for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The spreadsheet contains approximately 100 pharmaceutical products spanning multiple therapeutic categories, including controlled substances, biologics, injectables, inhalants, ophthalmic preparations, and intrauterine devices. Products listed include both brand-name drugs (such as ABRAXANE, ADVAIR DISKUS, NEXIUM, SPIRIVA RESPIMAT, and VICTOZA) and generic equivalents, with specific formulations, strengths, package sizes, NDC numbers where available, and estimated quantities of one unit per product.

The forecast supports FDA's research mission to evaluate generic drug equivalence, assess drug quality associated with adverse events, conduct physicochemical characterization and in-vitro release testing comparisons between branded and generic products, and perform drug assay methodology analysis. The solicitation is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) with a small business size standard of 1,300 employees. The FDA is conducting market research to identify small business sources and other capable suppliers capable of providing these pharmaceuticals as needed for laboratory, animal, and human research studies conducted by CDER in collaboration with internal and external investigators.